Ophthalmology 360
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Industry Council
    • Advisory Board

What are you looking for?

  • Anterior Segment
  • Cataract
  • Cornea and External Disease
  • Diabetic Macular Edema
  • Dry Eye
  • Early Onset Cataracts
  • Exclusives
  • General
  • Geographic Atrophy
  • Glaucoma
  • Industry News
  • Inherited Retinal Disease
  • IOLs
  • Neurotrophic Keratitis
  • Ocular Surface Disease
  • Oculoplastics
  • Optometry
  • Pediatrics
  • Practice Management
  • Presbyopia
  • Refractive Surgery/Vision Correction
  • Residents & Young Ophthalmologists
  • Retina
  • Retina Care 360
  • Retinopathy of Prematurity
  • Spotlight Series
  • The Interventional Glaucoma Project
  • The Ophthalmic Project
  • Trending Topics
2nd Annual Photo Contest - Enter Here!
Ophthalmology 360
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Industry Council
    • Advisory Board
Home > Conference Roundup > Outcomes associated with a violet light-filtering diffractive full-range of vision IOL
  • Conference Roundup

Outcomes associated with a violet light-filtering diffractive full-range of vision IOL

Ophthalmology 360

Karolinne Rocha, MD, PhD, of the Medical University of South Carolina, spoke with Ophthalmology 360 about a study she presented at the AAO 2025 Annual Meeting, which found that the new generation of full vision range of lenses have a better tolerance to residual refractive error.

Karolinne Rocha, MD, PhD:

Hi. I am Karolinne Rocha. I’m director of Cornea & Refractive Surgery at Storm Eye, Medical University of South Carolina in Charleston. We presented a study at the AAO this year that was very interesting. We looked at refractive outcomes, tolerance of residual astigmatism, and night vision symptoms of a new diffractive full vision range IOL with a violet light blocker. What we did in our study, we looked at, again, refractive outcomes, but also we simulated astigmatism post-op with the rule oblique and against the rule. We know that especially with diffractive multifocal patients, the patients, they usually don’t tolerate astigmatism. The distance vision really drops with any residual astigmatism. That’s why this study was so important, especially for the new generation full vision range intraocular lenses.

In our study was very interesting and we are very surprised because more than 90% of patients, they were able to see 20/40 or better, with up to 1.5 diopters of with the rule astigmatism and one diopter of oblique and against the rule astigmatism. Again, the patients, despite the astigmatism, they were still able to have a good distance vision, full vision range with those lenses. Patients were able to tolerate with the rule more than against the rule and oblique astigmatism. In terms of night vision symptoms, dysphotopsies, we use the IOL task force questionnaire, the IOLs questionnaire to assess night vision symptoms with diffractive optics. We’ve been using the same questionnaire for all our IOL studies. But for halos, starbursts, snowballs, the symptoms were severe in only 3% of patients and glare 7%. Really great for performance.

I think we’re excited about the new generation of full vision range of lenses, that they have a great dysphotopsia profile and they definitely have a better tolerance to residual refractive error.

Share

Related Content

  • The Interventional Glaucoma Project

Improving Patient Experience and Practice Workflow With an Interventional Glaucoma Approach

  • The Interventional Glaucoma Project

Data-Driven Focus on Interventional Glaucoma Care

  • Conference Roundup

Cryopreserved amniotic membrane significantly improves ocular surface integrity in patients with severe keratoconjunctivitis sicca and neurotrophic keratopathy

  • Conference Roundup

CAM360 with a collagen shield provides rapid epithelial healing with better tolerability and safety than when used with bandage contact lenses

  • Conference Roundup

Enhanced monofocal IOLs provide better intermediate vision with no rings or dysphotopsia

  • Conference Roundup

Phase 1/2 CLARA study shows AURN001 improves BCVA compared with standard of care for corneal endothelial dysfunction

Share

Editor's Picks

  • Neurotrophic Keratitis

Topical insulin shows real-world benefit in neurotrophic keratopathy

  • Retina

GLP-1 RAs have protective effects against AMD

  • Retina

Four-month injection intervals appear safe for long-term stable nAMD

Advisory Board

Saad Ahmad, MD

Ahmad A. Aref, MD, MBA

Roomasa Channa, MD

David Chow, MD, FRCS(C)

Sally L. Baxter, MD, MSc

Neel R. Desai, MD

Nadia Haqqie, MD

Simon Fung, MD, FRCOphth

Sumit Garg, MD

Ross Lakhanpal, MD, FACS

Sanjai Jalaj, MD

Anton Kolomeyer, MD, PhD

Shan Lin, MD

Steven R. Sarkisian, Jr., MD

See All
Ophthalmology 360

Ophthalmology 360® is a dynamic digital platform dedicated to advancing the field of eye care.

Get to Know Us

  • Home
  • About Us
  • Media Partners
  • Advertising Policy
  • Our Advisory Board

Sign up for our Newsletter

Sign up for our Newsletter to get our newest articles instantly!

  • Privacy Policy
  • Advertising Policy
  • Medical Disclaimer
IHM Logo

2026 Ophthalmology 360 is a trademark of International Healthcare Media, LLC. All rights reserved

  • MedJournal360 Icon
  • RareDisease360 Icon
  • MyHero360 Icon
  • Optometry360 Icon
  • Ophtalmology360 Icon